

Analytical Ancestry: “Firsts” in Fluorescent Labeling of Nucleosides, Nucleotides, and Nucleic Acids

Larry J. Kricka^{1*} and Paolo Fortina^{2,3}

BACKGROUND: The inherent fluorescent properties of nucleosides, nucleotides, and nucleic acids are limited, and thus the need has arisen for fluorescent labeling of these molecules for a variety of analytical applications.

CONTENT: This review traces the analytical ancestry of fluorescent labeling of nucleosides, nucleotides, and nucleic acids, with an emphasis on the first to publish or patent. The scope of labeling includes (a) direct labeling by covalent labeling of nucleic acids with a fluorescent label or noncovalent binding or intercalation of a fluorescent dye to nucleic acids and (b) indirect labeling via covalent attachment of a secondary label to a nucleic acid, and then binding this to a fluorescently labeled ligand binder. An alternative indirect strategy involves binding of a nucleic acid to a nucleic acid binder molecule (e.g., antibody, antibiotic, histone, antibody, nuclease) that is labeled with a fluorophore. Fluorescent labels for nucleic acids include organic fluorescent dyes, metal chelates, carbon nanotubes, quantum dots, gold particles, and fluorescent minerals.

SUMMARY: Fluorescently labeled nucleosides, nucleotides, and nucleic acids are important types of reagents for biological assay methods and underpin current methods of chromosome analysis, gel staining, DNA sequencing and quantitative PCR. Although these methods use predominantly organic fluorophores, new types of particulate fluorophores in the form of nanoparticles, nanorods, and nanotubes may provide the basis of a new generation of fluorescent labels and nucleic acid detection methods.

© 2009 American Association for Clinical Chemistry

In science, being the first to invent or describe a method or a composition of matter or expound a valid theory carries significant prestige. Tangible rewards for being first may include granting of a limited-term monopoly in the form of a patent or international recognition and the award of major scientific prizes (1). Determining who was first is not always straightforward, however. History is replete with corrections and conflicts on this highly charged and often commercially sensitive topic, as is evident from the controversy that surrounds such familiar concepts as calculus and items such as the slide rule, laser, and telephone (2–5).

In this review, we trace the origins of fluorescent labeling of nucleic acids, tracking the evolution of ideas and emergence of techniques and examining the associated intellectual property via issued patents. Our focus is on who was first to describe or discover a particular type of compound or technique or property of matter. This information is of particular significance for inquiries into the validity of patents through anticipation and obviousness analysis (6). As others have noted about earliest dates, however, they “have a way of becoming unfixed as the history of the subject is further studied” and “there is no way of knowing what future students will unearth” (7). The scope of the article is limited to labels that produce fluorescence upon irradiation with excitation energy of the appropriate wavelength. We do not consider phosphorescent labels, labels that can be converted to a fluorophore (e.g., fluorescein diacetate nanocrystal labels) (8), or labels that act on other substances to produce fluorescent products (e.g., alkaline phosphatase label and a fluorogenic substrate).

The scientific literature is now enormous. PubMed includes more than 17 million citations back to the 1950s (9), the CAPLUS database contains more than 27 million patent and journal articles (10), and more than 7 million US patents have been issued (11). We have searched extensively in this massive collection of abstracts, papers, reviews, and books; however, an ever-present danger is that we have overlooked an obscure publication or a public disclosure at a scientific meeting captured in an abstract book that did not make its way into a library or into a public database. Likewise,

¹ Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; ² Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Jefferson Medical College, Philadelphia, PA; ³ Dipartimento di Medicina Sperimentale, Università “La Sapienza,” School of Medicine, Rome, Italy.

* Address correspondence to this author at: Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104. Fax: 215 662 7529; e-mail kricka@mail.med.upenn.edu.

Received August 12, 2008; accepted January 15, 2009.

Previously published online at DOI: 10.1373/clinchem.2008.116152

FLUORESCENCE	NUCLEIC ACIDS
1852 Stokes Law	
1853 Term “fluorescence” coined by Stokes	
1871 Fluorescein synthesized	1869 DNA isolated by Miescher
1897 Term “fluorophore” coined by Meyer	1889 Term “nucleic acid” coined by Altman
1911 Fluorescence microscope developed by Heimstaedt and Lehman	
1919 Fluorescent staining	
1924 Fluorescence staining using Feulgen reaction	1929 DNA structural components identified by Levene
1929 Epifluorescence microscope developed by Ellinger and Hirt	
	1952 ³² P labeling
	1953 Helix structure of DNA described by Watson and Crick
	1955 Synthesis of a dinucleoside phosphate
1962 Labeling of base	
1963 X-ray fluorescence labeling with bromine	
1963 In vivo enzymatic labeling	
1963 Ribose labeling by periodate method	
1967 Naturally fluorescent modified base	
1969 In vitro enzymatic labeling	
1970 Energy-transfer labels	
1971 Labeling of modified base	
1973 Labeling of intact ribose	
1973 Labeling of 5'-phosphate	1975 Southern blotting
1980 Fluorescent direct and indirect probe patent filed	
1983 Labeling of 3'-phosphate	1983 Commercial DNA synthesizer
	1985 PCR patent filed
1993 Infrared fluorescence labeling	1986 Commercial DNA sequencer
2000 Quantum dot label	
2004 Carbon nanotube label	
2005 Gold nanorod label	

Fig. 1. Landmarks in fluorescence and nucleic acid chemistry.

P, patent priority.

we have inevitable linguistic biases, and publications in some languages may have escaped our scrutiny.

FLUORESCENCE IN NUCLEIC ACID ANALYSIS

Fluorescence was observed in antiquity, but the science of fluorescence dates back to work by Sir George Stokes (Stokes Law of Fluorescence: the wavelength of fluores-

cence emission is greater than that of the exciting radiation) who coined the term “fluorescence” in 1852 (Fig. 1) (12). The term “fluorophore” to describe a chemical group associated with fluorescence was coined by Richard Meyer in 1897 (13). Other important landmarks were the synthesis of the fluorescent dye, fluorescein, by Adolph von Baeyer in 1871 (14)

and the development of the fluorescence microscope in 1911 by Heimstadt and Lehman (15) and the epifluorescence microscope in 1929 by Ellinger and Hirt (16). The range of fluorescence emission spans the electromagnetic spectrum from the x-ray (<10 nm) through the visible (380–750 nm) to the infrared (IR)⁴ (630 nm to 3000 μm) regions of the spectrum. Nucleic acids have been labeled with fluorophores with emissions in the x-ray (17), visible (18, 19), and IR (20, 21) regions of the spectrum.

As the discovery of fluorescence precedes that of nucleic acids, the starting point of our inquiries was the history of nucleic acids. The nucleic acid DNA was first isolated in 1869 by Friedrich Miescher (22). However, following its successful separation into a protein and an acid molecule, his pupil, Richard Altmann, named it “nucleic acid” in 1889 (23). The structural components (the 4 bases, the sugar, and the phosphate chain) were identified in 1929 by Phoebus Levene, and he showed that the components of DNA were linked in the order phosphate-sugar-base (24). He called each of these units a nucleotide and proposed that the DNA molecule consisted of a string of nucleotides linked together via the phosphate “backbone” of the molecule. Subsequently, in 1953, Watson and Crick solved the 3-dimensional structure of the DNA molecule and showed it to be a double helix (25).

The study of the fluorescence of nucleic acids and the development of fluorescently labeled nucleic acids is set against a historical background of fluorescent methods for bioanalysis (26). Fluorescence was already established by the late 1940s for both *in vitro* (27) and *in vivo* applications (28) and had been in use in other areas of analysis since at least 1922, when Hadding used x-ray fluorescence to analyze minerals (29). By the 1930s, patents had been granted covering fluorescence-detecting apparatus useful in the diagnosis of disease (30), and during the 1960s and 1970s, numerous patents were issued on the use of fluorescence for analysis of cells (31, 32) and virus particles (33). Filing of patents for fluorescent nucleic acid probes began in the early 1980s and included directly labeled probes (34–37) and indirectly labeled probes (34, 35, 38, 39). Filings for the application of fluorescent labels in sequencing also began to appear in the 1980s for both direct (40, 41) and indirect (42, 43) labeling.

Study of the fluorescence of bases, nucleosides, nucleotides, and their polymers has a long history dating back to the early part of the 20th century (44–46). However, the fluorescence of nucleic acids is weak and has not proved particularly useful analytically, except in the case of nucleic acids containing certain modified bases that are naturally fluorescent. The first to be described was a base designated as “Y” [wybutosine (γW)] (47) in L-phenylalanyl-tRNA^{Phe}, and this has been chemically modified to another fluorescent form of the base by treatment with ammonium carbonate (48). Subsequently, other fluorescent modified bases (e.g., pseudo uridine, 4-thiouridine, dihydrouridine, N4-acetylcytidine, 7-methylguanine, 7-methylinosine) were discovered (49–53).


In view of the limited fluorescent properties of nucleic acids, the application of fluorescence in nucleic acids analysis has followed several pathways (Fig. 2). Direct labeling can be achieved by covalent labeling of nucleic acids with a fluorescent label or noncovalent binding (staining or intercalation) of a fluorescent dye to nucleic acids (Fig. 2A, B). Indirect labeling can be achieved by first covalently attaching a secondary label to a nucleic acid and then binding this to a fluorescently labeled ligand binder (Fig. 2C). Alternatively, a nucleic acid can be bound to nucleic acid binder molecule (e.g., antibody, antibiotic, histone, antibody, nuclease) that is labeled with a fluorophore (Fig. 2D).

MOTIVATION FOR FLUORESCENCE LABELING

By and large, the motivation for combining fluorescence and nucleic acids has been to provide a nonisotopic label (tag or marker or reporter group) that has a detectable signal to study nucleic acid sequence, structure, structural dynamics, protein and ligand interactions, or hybridization with other nucleic acids (probing) (34) (fluorescent labeling of the broad class of receptors, specifically nucleic acids, has been described (54)). The impetus for synthesizing fluorescent nucleoside or nucleotide analogs has been for photoaffinity labeling, preparing coenzyme analogs, improving detectability in chromatographic analysis, and rendering DNA fragments detectable in polyacrylamide gel electrophoresis as part of dideoxy DNA sequencing protocols, or in quantitative PCR reactions.

It should be appreciated that the genesis of some fluorescently labeled nucleic acids, nucleotides, or nucleosides has not always been motivated by a specific desire to develop fluorescently labeled materials. For example, nucleic acids fluorescently labeled at the C-8 of guanine bases have been isolated or synthesized in studies of the mechanism of the interaction of DNA and carcinogens such as 2-acetylaminofluorene (AAF) (55).

⁴ Nonstandard abbreviations: IR, infrared; γW , wybutosine; AAF, 2-acetylaminofluorene; NIR, near infrared; CNT, carbon nanotube; tRNA, transfer RNA; sRNA, soluble RNA; 5BrU, 5-bromouracil; TdT, terminal deoxynucleotidyl transferase; TMR, tetramethylrhodamine; YOYO, oxazole yellow homodimer; TO, thiazole orange; TOTO, thiazole orange homodimer; dsDNA, double-stranded DNA; ssDNA, single-stranded DNA; TMV, tobacco mosaic virus.



SCOPE AND SELECTION OF FLUORESCENT LABELS

The vast majority of fluorescent nucleic acid labeling studies have used organic fluorescent dye molecules (e.g., fluorescein, rhodamine); however, fluorescent metal chelates that have a long-lived time-resolvable signals (e.g., europium chelates) and various organic (e.g., carbon nanotubes) and inorganic (e.g., quantum dots, gold particles, fluorescent minerals) particles have also been used. In most cases, the fluorescent labels used for nucleic acids had been previously used as labels in immunoassays.

Considerations in the choice of the fluorophore include factors such as fluorescence quantum yield, Stokes shift, fluorescence emission spectrum (including time-resolvability) and ability to use several fluorophore labels simultaneously, susceptibility to photobleaching, and reduction of background interference, as in the case of time-resolved fluorescent labels based on lanthanide chelates (37, 56) and cyanine (57) and metal (20, 21) chelate-based IR labels.

At a pragmatic level, the choice of the fluorophore has been guided by its availability and ease of attachment, and in this regard various activated fluorescein molecules have enjoyed considerable popularity (e.g., fluorescein isothiocyanate). The signal from a fluorescent label is determined in part by the fluorescence quantum yield of the fluorophore, and, the near unity quantum yield of fluorescein underlies the popularity of this label. The fluorescent signal emitted from a fluorophore depends directly on the intensity of the exci-

tation light. As the excitation light intensity increases, however, there is a tendency for organic molecules to decompose, and this leads to photobleaching and loss of fluorescent signal. Inorganic fluorophore labels such as quantum dots are not prone to photobleaching, and this has spurred their application in nucleic analysis. The Stokes shift is another important characteristic of a fluorophore label. A large Stokes shift is advantageous because it minimizes interference by the excitation light in the measurement of the fluorescence emission. Stokes shifts of up to 200 nm are possible with semianaphthofluorone type dyes (Stokes shift for fluorescein is approximately 20 nm) (58). An emission wavelength in the near infrared (NIR) can be advantageous for a fluorophore label, as this minimizes interfering fluorescence from biological samples, reduces scattering, increases tissue penetration for the signal, and allows the use of low-cost laser diode excitation sources (37, 56). Also, the overall structure of a fluorophore label can influence the ability of a labeled nucleic acid to serve as a substrate for an enzyme. This has been a critical factor in the development of labeled nucleotides for sequencing using a polymerase, and the linker that attaches a fluorophore label to a nucleotide has a pronounced effect on the effectiveness of a DNA polymerase to incorporate a fluorescent nucleotide (59).

An interesting trend has been the impact of micro- and nanotechnology on direct and indirect fluorescent labeling of nucleic acids in the form of micro- or nanosized organic or inorganic particles. The scope of

this strategy includes quantum dots (60–62), metal nanoparticles and nanorods (63), carbon nanotubes (CNTs) (64, 65), dye-doped core-shell particles (66), dyed latex particles (67, 68), and liposomes or polymer shells filled with fluorescent particles (e.g., quantum dots, dyed polymer beads, and naturally occurring minerals such as eucryptite) (69).

Fluorescent metal chelates. A chelate-based strategy for fluorescent labeling presents an interesting aspect of determining who was first to describe a particular type of fluorescent labeling. A patent published in 1977 describes labeling of “target substance” with rare-earth complexes (70), and another patent with a priority in 1979 describes labeling of antigens with fluorescent metal chelates (71). Because a nucleic acid such as DNA is an example of a target substance and is an antigen, these generic claims could be viewed as a disclosure of fluorescent metal chelate labeling of a nucleic acid. Likewise, another patent (priority 1981) describes the fluorescent lanthanide chelate labeling of a “biologically active substance,” which of course would include a nucleic acid (72). Subsequently, lanthanide chelates were specifically described in a patent (priority 1981) as labels for DNA in a sandwich hybridization assay (37).

Quantum dot. A quantum dot is a nanocrystal composed of periodic group II–VI (e.g., CdSe, CdS), II–V (InP, InAs), or IV–VI (e.g., PbTe, PbS) materials. It can contain as few as 10–50 atoms and have a diameter as small as 2–10 nm (73–75).

Advantages of quantum dots compared with conventional organic fluorescent dyes include high quantum yield (bright signal), less susceptibility to photobleaching, and a fluorescence emission wavelength that is directly related to the diameter of the quantum dot. A quantum dot is usually coated with a shell to improve quantum efficiency and stability. The shell surface of a “core/shell” quantum dot can be functionalized by treatment with organic molecules (e.g., silanes) that provide points of attachment for nucleosides or nucleotides (60, 61) or DNA (62). Early suggestions for the use of quantum dots are to be found in articles published in 1998 (76, 77). Interestingly, quantum dots had been attached to nucleic acids such as transfer RNA (tRNA) as part of a quantum dot synthesis scheme in which the tRNA, dispersed in a gel matrix, acted as an ion-exchange/nucleation site for formation of the quantum dots (e.g., AgO, CdS) (78).

Metal nanoparticle or nanorod. A starting point for gold as a fluorescent label was the description of the fluorescence of bulk gold by Mooradian in 1969 (79). Subsequently, the fluorescence of gold nanoparticle clusters and nanorods (80, 81) was demonstrated. In hindsight, all of the early work using colloidal gold-labeled


nucleic acids (82) could be considered fluorescent labeling, as could the DNA self-assembly of gold nanoparticle studies (83), albeit in neither case was the gold detected by fluorescence. Recently, however, fluorescent gold nanorod labels (17 nm diameter, 230 nm long; emissions at 743 and 793 nm) have been used to label DNA. The nanorod label was attached to thiolated DNA via Au-SH binding (80).

Carbon nanotube. A CNT is a nanometer-diameter cylindrical carbon molecule, and as discovered in 2002, it fluoresces in the near-infrared part of the spectrum (84). A CNT can be derivatized to contain carboxyl groups, and these serve as points of attachment for fluorescent labeling of nucleic acids (64, 65).

DIRECT COVALENT LABELING OF NUCLEIC ACIDS WITH A FLUORESCENT LABEL

There are several sites on a nucleic acid molecule at which covalent attachment is possible, including attachment sites on the sugar, the phosphate, and the different purine and pyrimidine bases (Fig. 3) (85). Most labeling reactions are designed to target a specific location on a nucleic acid, but indiscriminate covalent labeling is possible using nitrenes that react at random with other molecular species by interatomic radical insertion reactions involving, for example, carbon–hydrogen, oxygen–hydrogen, and nitrogen–hydrogen bonds. This highly reactive functional group has been used to attach an ethidium fluorophore to DNA by reacting the DNA with ethidium azide (86). This strategy is analogous to other photochemically generated free radical–based labeling reactions developed in the 1960s for proteins (87).

Labeling the sugar. It appears that the first example of covalent labeling of a nucleic acid at any position involved the ribose sugar and can be attributed to Feulgen in 1924 (18, 88). Acid hydrolysis of DNA causes depurination, and the liberated aldehyde group of the ribose sugar is then available to react with the amine group of a pararosaniline (fuchsin) Schiff reagent. A specifically fluorescent Feulgen method was published by Ornstein et al. in 1957 (89) and was based on acriflavine as the Schiff-type aldehyde reagent; this produced a green fluorescent staining of nuclei in tissue sections. The scope of this reaction was subsequently expanded to other fluorogenic Schiff reagents by Kasten et al. (90). The first example of covalent labeling of a nucleic acid in solution, as opposed to a tissue section, was described in 1958 by Kissane and Robins (19). They were interested in developing a fluorometric assay for DNA in brain tissue. Their method entailed depurination of the DNA followed by



reaction of the aldehyde group in the deoxyribose with 3,5-diaminobenzoic acid to produce a fluorescent Schiff base product.

An alternative nondepurinating labeling method was described by Churchich in 1963 (91). Periodate-oxidative ring opening of the ribose sugar ring of solu-

ble RNA (sRNA) and subsequent reaction of the aldehydes produced with the reactive amino groups of acriflavine (3,6-diamino-10-methylacridine) gave fluorescently labeled sRNA. This was used to determine the relaxation time of the sRNA by a fluorescence polarization method.

Fluorescent labeling of an intact sugar at the 3' or 5' position dates back to 1973 (92). Thymidine, blocked at the 3' or 5' position, was reacted with α -naphthyl isocyanate to produce thymidine 3'- or 5'-naphthylcarbamate. Subsequently, the scope of the fluorophores attached to these sugar ring positions was expanded to include other well-known fluorophores such as anthracene (93) and dansyl (94). Alternative strategies use 5'-*N*-protected 5'-amino phosphoramidites, and after deprotection, the amino group is reacted with an activated fluorescent dye (e.g., fluorescein isothiocyanate) (95).

Labeling via a reaction that bridges the 3' and 5' position was also developed in 1973 (96). ATP was trinitrophenylated by simultaneous reaction at the 2'- and 3'-hydroxyl groups of the ribose sugar to give an ATP derivative that fluoresced in ethanol-water solutions.

Labeling the phosphate. The first fluorescent labeling of the phosphate group at the 5' position dates back to 1973 (97). This was achieved by first synthesizing dansyl or anthraniloyl phosphoromorpholidate derivatives and then reacting these with the 5'-phosphate of tRNA. Labeling of the 3'-phosphate was reported by Gohlke et al. (98) as part of studies to make fluorogenic substrates for a ribonuclease assay (e.g., 2',5'-bis-tert-butyl dimethylsilyl 3'-uridine-4-methylumbelliferone-7-yl)phosphate).

In 1989, the scope of phosphate labeling was expanded by labeling an internucleotide phosphate (99). Oligonucleotides synthesized to contain reactive phosphorothioate diesters at specific locations were dansylated to form fluorescent phosphorothioate triesters.

Labeling the base. Direct fluorescent labeling of a base can be traced back to work on the photoreaction between skin-photosensitizing furocoumarins and flavin mononucleotide (100) and the expansion of the reaction to pyrimidine bases of nucleic acids, such as thymine (101–106). Usually, labeling of thymine is problematic because the 5-methyl substituent blocks the reactive 5-position. However, fluorescent labeling that involves reaction at the 5- and 6-positions of a thymine base or other pyrimidine bases is possible via a photochemically induced cyclo-addition reaction with various furocoumarins (e.g., 5-methoxypsoralen) (103). Thymine has also been rendered fluorescent by an alkylation reaction to produce a 1-(2,3-dioxobutyl) thymine derivative (107).

Subsequently, guanosine was labeled at the 8-position with *N*-acetoxy-*N*-2-fluorenyl acetamide as part of studies on the reactions of the carcinogen *N*-acetoxy-*N*-2-fluorenylacetamide with guanosine (55). Ring amine groups of guanine can also be labeled via reaction with a diazotized fluorescein derivative (108).

Labeling of AMP or dAMP, or labeling of A in poly(A) [single stranded or complexed with poly(U)], was achieved in 1974 by reaction with 9-bromomethylanthracene (109). Reaction occurred at the amino group at the 6-position and also at the 1-position in the case of the mononucleotide. Fluorescent labeling of adenosine and cytidine by a reaction that bridges the 1- and 6-position of adenine and the 3- and 4-position of cytidine to produce etheno compounds can be achieved via a cyclization reaction with chloroacetaldehyde. This was first described by Kochetov et al. (85) and developed for fluorescent labeling purposes by others (110, 111).

The synthesis of a fluorescent 1-(2,3-dioxobutyl) uracil derivative was reported in 1978 (107). Later, Saito et al. (112) adapted a photochemical alkylation reaction to make strongly fluorescent 5-pyrenyl uridine.

Labeling of aminoacylated nucleic acids. Some nucleic acids, such as tRNA, are modified by addition of an amino acid, and reactive chemical groups on the amino acid provide convenient sites for covalent attachment of a label. This is exemplified by the naphthoxyhpacetylation of the amino group in the amino acid moiety in tRNA using a 2-naphthoxy acetyl ester of *N*-hydroxysuccinimide. This synthetic procedure was described in 1968 using a series of tRNAs (e.g., tRNA^{Asp}) (113) and applied as a fluorescent labeling strategy several years later for tRNA^{Ile} (114).

Labeling of modified bases and nucleic acids. Several of the modified bases that occur in the nucleic acids of some organisms have chemically reactive side chains that are suitable for attachment of fluorescent labels (115). The first examples of this type of labeling were reported in 1971. The thiol substituent in 4-thiouridine and 4-thiouracil was reacted with a fluorescent coumarin derivative to give the fluorescent sulfide (116). Another contemporaneous route to a fluorescent tRNA derivative involves photodimerization of 4-thiouridine with cytidine, followed by sodium borohydride reduction of the photodimer (117). Table 1 lists other modified bases that have been fluorescently labeled (see review by Favre and Thomas (118)).

Labeling via enzymatic incorporation of a fluorescent analog or fluorescent base or modified base. Among the earliest examples is to be found in the work of Zeitz and Lee (1963) (17). As part of their studies on the radio-sensitivity of DNA, they replaced thymine with 5-

Table 1. Fluorescence and fluorescent labeling of nucleic acids.

Discovery (first use, publication, or patent)	Reference	Discovery (first use, publication, or patent)	Reference
Natural fluorescence		5- and 6-position	Musajo et al. (103), Musajo et al. (104)
Free bases	Heyroth and Loofbrow (44)	U	
Nucleosides and nucleotides	Udenfriend and Zaltman (26)	1-position	Lee et al. (107)
Oligonucleotides	Eisinger et al. (168), Gueron et al. (169)	3-position	Yoshida et al. (176)
Poly nucleotides	Konev (45)	Amino acid group (tRNA)	
"Modified" or "odd" base		Asp	Gillam et al. (113)
Y	RajBhandary et al. (47)	"Modified" or "odd" base	
4-Thio U	Lipsett (170)	4-thiouridine	Fave et al. (51)
N4-acetylcytidine	Pochon et al. (53)	Modified Y (YW)	Yoshikami and Keller (48)
Covalent fluorescent labeling		9-methyladenine	Kochetov et al. (85)
Sugar		1-methylcytidine	Kochetov et al. (85)
Depurinated sugar	Feulgen and Rossenbeck (18)	Pseudouridine (Ψ)	Yang and Söll (50)
Ring-opened sugar	Churchich (91)	2-thio-5-(N-methylaminomethyl)uridine	Yang and Söll (50)
Intact sugar		Q (queousine)	Yang and Söll (49), Pingoud et al. (177)
2' position	Hiratsuka and Uchida (96)	X [(3-(3-amino-3-carboxypropyl)U]	Schiller and Schechter (178)
3' position	Bienvieue and Tournon (92)	X-47	Faulhammer et al. (179)
5' position	Bienvieue and Tournon (92)	pre-Q ₁	Kasai et al. (180)
Bridging 2' and 3' positions	Hiratsuka and Uchida (96)	Under modified Y	Kuchino et al. (181)
Phosphate		Xanthosine	Macklin et al. (182)
5'	Yang and Söll (97)	Enzymatic incorporation of fluorescent nucleotides or analogs	
3'	Gohlke et al. (98)	TdI-catalyzed	Rozovskaia et al. (119)
Base		T ₄ RNA ligase-catalyzed	Richardson and Gumpert (121)
A		RNA polymerase-catalyzed	Ward et al. (183), Ward et al. (184)
Position not known	Pochon et al. (53)	Polynucleotidyl phosphorylase-catalyzed	Zhenodarova and Kiyagina (185)
1-position	Pochon and Perrin (109)	DNA polymerase-catalyzed	Ried et al. (186)
6-position	Pochon and Perrin (109)	Avian myeloblastosis virus (AMV) reverse transcriptase	Prober et al. (187)
5- and 6-position	Barrio et al. (110)	Noncovalent labeling	
G		Staining	
2-position	Jeffrey et al. (171), Koreeda et al. (172)	Eosin	von Provezek (126)
7-position	Casperson et al. (173)	Nucleic acid binder	
8-position	Kriek et al. (55)	Antibiotic	Crissman et al. (153)
C		Histone	Lewis (154)
4-position	Draper and Gold (174)	Antibody	Beiser et al. (155)
6-position	Pochon et al. (52), Leng et al. (175)	Nuclease	Benjaminson et al. (156)
3 and 4-position	Barrio et al. (110), Secrist et al. (111)	Restriction endonuclease	Taylor et al. (68)
T		Poly(U)	Cheung et al. (157)
3-position	Yoshida et al. (176)		

bromouracil (5BrU) in a DNA sample by growing *E. coli* B 15T⁻ in a medium containing 5BrU, and then detected the bromine atom in the incorporated 5BrU by irradiating the sample with x-rays and detecting the fluorescence emission of the bromine at approximately 0.1040 nm.

Subsequently, the availability of various enzymes facilitated development of in vitro protocols for labeling nucleic acids. These were originally developed for nonfluorescent labeling and subsequently expanded to include fluorescent labeling of nucleic acids. In vitro fluorescent labeling was initially achieved with an *E. coli* RNA polymerase-catalyzed incorporation reaction using a d(A-T) template and the fluorescent analogs of ATP, formycin, 2-aminopurine, or 2,6-diaminopurine. These same analogs were also attached to the terminus of a tRNA molecule using tRNA-CCA pyrophosphorylase (38, 39).

Other enzymes used for in vitro labeling include terminal deoxynucleotidyl transferase (TdT) that catalyzed the incorporation of fluorescent bases such as 3-O-acyl(fluorescein or rhodamine) UTP (119). A variant on this procedure used TdT to incorporate 4-thiouridine at the 3' end of DNA, and the thiol group of the incorporated 4-thiouridine was in turn labeled with fluorescein, eosin, or aminonaphthalene 1-sulfonic acid derivatives (120). T₄ RNA ligase is also useful for fluorescent labeling. By using fluorescein and tetramethylrhodamine (TMR) derivatives of P¹-(6-amino-hex-1-yl)-P²-(5'-adenosine), it was possible to introduce a fluorescent fluorescein or TMR label onto the 3'-hydroxyl group of RNA in good yield (121).

NONCOVALENT LABELING OF NUCLEIC ACIDS WITH A FLUORESCENT LABEL

The 2 principal methods of noncovalent labeling are direct methods in which a fluorescent dye or particle binds to a single- or double-stranded nucleic acid (staining) (Fig. 2B) and indirect methods in which a fluorescently labeled nucleic acid binding agent (e.g., avidin or an antibody) binds to a secondary label (e.g., biotin, iminobiotin) covalently attached to the nucleic acid (Fig. 2C) or to a specific structure, e.g., an RNA:DNA hybrid (Fig. 2D).

Direct noncovalent binding of fluorescent dyes to nucleic acids (staining). The scope of dye-binding detection methods encompasses dyes that bind to nucleotides (122), double- and single-stranded nucleic acid; dyes that have selectivity for double- vs single-stranded nucleic acid, DNA vs RNA (123); and dyes that bind to the minor groove, e.g., Hoechst 33258 (124), and the major groove, e.g., methyl green (125), of DNA.

Study of the interactions between fluorescent dyes

and nucleic acids traces back to the turn of the 20th century and studies on vital fluorochroming using eosin and erythrosin (126), and this in turn has its origins in the colorimetric histochemical staining reactions pioneered by Raspail in the early 1800s (127). Binding of the 10-methyl homolog of ethidium bromide to DNA was suggested in 1953 (128), and the intercalative binding of acridine, proflavine, acridine orange, and ethidium bromide to nucleic acids was demonstrated over the next decade (129–132). Ensuing years saw the introduction of superior variants of ethidium bromide, e.g., ethidium homodimer (133); intercalating dyes based on oxazoles [e.g., oxazole yellow homodimer (YOYO)] and thiazoles [e.g., thiazole orange (TO) and thiazole orange homodimer (TOTO)] that showed greater fluorescent enhancement when bound to double-stranded DNA (dsDNA) (134, 135); and dyes such as PicoGreen that show greater selectivity for dsDNA vs RNA or single-stranded DNA (ssDNA) (136).

Sensitive quantitative fluorescent DNA detection in solution using ethidium bromide was described in 1964 (131, 137, 138). However, the application of intercalating dyes to solid phase DNA detection, e.g., in agarose gels, is controversial (139). Aaij and Borst described this method in 1972 (140), inspired by the bright orange bands observed when DNA was separated in preparative CsCl-ethidium gradients, but an article in the following year has been more commonly cited (141).

Single-stranded nucleic acids can also be stained. For example, acridine orange staining of single-stranded virus RNA [tobacco mosaic virus (TMV)] was described in 1961 (142). Subsequently, other dyes that stain ssRNA, e.g., Cuproline blue–magnesium chloride (143), dyes for ssDNA including TOTO and YOYO (144), and also dyes such as Hoechst 33258 that are selective for dsDNA in the presence of RNA and for dsDNA in the presence of ssDNA (145) have been developed. Triple-stranded nucleic acids will also bind to ethidium bromide (137, 138, 146).

Generally, intercalating dyes show no sequence selectivity, but some dyes, such as ethidium bromide, bind to A-T base pair-rich regions (147), and TOTO binds preferentially to 5'-pyrimidine-pyrimidine-purine-purine-3' motifs in dsDNA (5'-CTAG-3' preferred binding site) (148).

Indirect noncovalent labeling via binding of fluorescent binding agents to secondary-labeled nucleic acids. Secondary labeling of a nucleic acid with an antigen or hapten provides a general route to indirect DNA labeling through subsequent binding of the secondary label to a fluorescently labeled binding agent.

Biotin and iminobiotin are secondary labels that provide a route to indirect fluorescent labeling of nucleic acids. For example, biotin covalently linked to a nucleic acid can be bound to an antibiotin antibody that is labeled with a fluorophore (34), a streptavidinylated particle such as a latex bead containing fluorophores (149), or a silica particle. Alternatively, the biotin secondary label can be bound to rabbit antibiotin antibody, and this in turn immunocomplexed with a goat antirabbit IgG labeled with a fluorophore (150).

Fluorescein is antigenic, and so a route to indirect fluorescent labeling a nucleic acid is to first label it with fluorescein and then react the fluorescein hapten with anti fluorescein antibodies that have been labeled with a fluorophore, e.g., fluorescein. This strategy was applied to detect DNA using fluorescein labeled RNA. The further indirect labeling of the RNA using fluorescein-labeled anti fluorescein antibodies produced a 5- to 10-fold amplification compared to direct detection of the fluorescein-labeled RNA probe (151). A similar strategy has been developed for biotin and iminobiotin ligands that will bind to fluorophore-labeled avidin or streptavidin (38, 39).

Somewhat analogous is the use of a dipalmitoylphosphatidyl secondary label that can be incorporated into the wall of a liposome that encapsulates a fluorescent dye. A dipalmitoylphosphatidyl-labeled DNA-containing liposome encapsulating sulforhodamine B exemplifies this strategy (152).

Indirect noncovalent labeling via binding of fluorescent binding agents to nucleic acid hybrids. A range of macromolecules show binding affinity toward nucleic acid sequences. By labeling these macromolecules with a fluorophore, it is possible to achieve indirect labeling of a nucleic acid. The range of macromolecules includes antibiotics (e.g., olivomycins) (153), histones (154), antibodies (155), nucleases (e.g., deoxyribonuclease) (156), inactive restriction endonucleases (e.g., *EcoR1*) (68), and of course, nucleic acids. For example, polyadenylated RNA can be labeled by hybridization to poly(U) (50–1000 bases) that is covalently attached to a dansylated 300-angstrom-diameter latex microsphere (157, 158).

Fluorescently labeled monoclonal antibodies capable of distinguishing DNA-RNA hybrid complexes from single-stranded DNA and RNA and double-stranded DNA and RNA can be used to fluorescently label a DNA-RNA hybrid (159, 160). This forms the basis of the monoclonal anti-DNA:RNA hybrid capture assay strategy (161).

DEGREE OF LABELING AND LOCATION OF LABELS

Labeling methods have been developed that control the location and number of fluorescent labels attached to a nucleic acid. The ability to attach a fluorescent label at a specific location has assumed importance for probes used in energy transfer assays.

Double labeling has been achieved with 2 natural fluorescent bases (e.g., pseudoU + dihydroU) (50), a natural fluorescent base plus labeled base (e.g., Y + 3'-acridine) (162), or 2 labeled bases (e.g., 3'-acridine + 5'-anthrinoyl) (50). More recently, double labeling of the same oligonucleotide has assumed particular importance in the context of energy transfer probes, in which the donor and acceptor labels are located sufficiently close to quench fluorescence signal generation. Such probes are now widely used in the form of TaqMan probes for quantitative PCR assays (163), energy transfer primers for DNA sequencing (164, 165), and molecular beacons (166, 167).

Conclusions

Fluorescently labeled nucleosides, nucleotides, and nucleic acids continue to be important types of reagents for biological assay methods and underpin current methods of chromosome analysis, gel staining, DNA sequencing, and quantitative PCR. These methods use predominantly organic fluorophores, but nanotechnology is now offering new types of particulate fluorophores in the form of nanoparticles, nanorods, and nanotubes that may provide the basis of a new generation of fluorescent labels and nucleic acid detection methods.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

Authors' Disclosures of Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:

Employment or Leadership: None declared.

Consultant or Advisory Role: None declared.

Stock Ownership: None declared.

Honoraria: None declared.

Research Funding: None declared.

Expert Testimony: L.J. Kricka, Applied Biosystems.

Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.

Acknowledgments: The authors thank Sonny Mark for graphic design work and Judith Currano for assistance with literature searches.

References

- Nobel Foundation. Nobelprize.org. <http://nobelprize.org/> (Accessed February 2009).
- Encyclopedia Britannica. Sir Isaac Newton. <http://www.britannica.com/EBchecked/topic/413189/Sir-Isaac-Newton> (Accessed February 2009). See information on the Leibniz and Newton calculus controversy.
- Encyclopedia Britannica. The patent dispute regarding the invention of the laser. <http://www.britannica.com/EBchecked/topic/435352/William-Oughtred> (Accessed February 2009).
- Wikipedia. Slide rule. http://simple.wikipedia.org/wiki/Slide_rule (Accessed February 2009).
- The Great Idea Finder. <http://www.ideafinder.com/history/inventions/telephone.htm> (Accessed February 2009).
- United States Patent and Trademark Office. Appendix L Patent Laws. http://www.uspto.gov/web/offices/pac/mppe/consolidated_laws.pdf (Accessed February 2009).
- Conn HJ. The history of staining. Geneva, NY: Biological Stain Commission, WF Humphries Press, 1933:141 pp.
- Chan CP, Tzang LC, Sin KK, Ji SL, Cheung KY, Tam TK, et al. Biofunctional organic nanocrystals for quantitative detection of pathogen deoxyribonucleic acid. *Anal Chim Acta* 2007;584:7–11.
- U.S. National Library of Medicine, PubMed. <http://www.ncbi.nlm.nih.gov/pubmed/> (Accessed February 2009).
- Chemical Abstracts Service. A Division of the American Chemical Society. <http://www.cas.org> (Accessed February 2009).
- United States Patent and Trademark Office. <http://www.uspto.gov> (Accessed February 2009).
- Stokes GG. Mathematical and physical papers. Vol. 1–5. <http://tinyurl.com/b63592> (Accessed February 2009).
- Meyer R. Zeitschrift für Physikalische Chemie, Stochiometrie und Verwandtschaftslehre. *Zeit Phys Chem* 1897;24:468. [German]
- von Baeyer A. Ueber eine neue klasse von farbstoffen. *Ber Dtsch Chem Ges* 1871;4:555–8. [German]
- Kasten FH. The origins of modern fluorescence microscopy and fluorescence probes. In: Kohen E, Hirschberg JG, eds. *Cell structure and function by microspectrophotometry*. San Diego: Academic Press; 1989.
- Ellinger P, Hirt A. Mikroskopische untersuchungen an lebenden organen. I. Mittheilung: methodik: intravitalmikroskopie. *Zeitschrift Anatomie Entwicklungs-Geschichte* 1929;90:791–802. [German]
- Zeit L, Lee R. Bromine analysis in 5-bromouracil-labeled DNA by X-ray fluorescence. *Science (Wash DC)* 1963;142:1670–3.
- Feulgen R, Rossenbeck H. Mikroskopisch-chemischer nachweis einer nucleinsaure vom typus der thymonucleinsaure und die darauf beruhende elektive farbung vom zellkernen in mikroskopischen preparaten. *Preparaten Z Phys Chem* 1924;135:203–48. [German]
- Kissane JM, Robins E. The fluorometric measurement of deoxyribonucleic acid in animal tissues with special reference to the central nervous system. *J Biol Chem* 1958;233:184–8.
- Middendorf LR, Patonay G, inventors; Li-Cor, Inc. (Lincoln, NE, assignee). Sequencing near infrared and infrared fluorescence labeled DNA for detecting using laser diodes. US Patent 5,230,781. 1993 Jul 27.
- Seiji T, Mitsuo K, Watanabe H., inventors; Hitachi Chemical Co Ltd., assignee. Pigment for fluorescence labeling, organism-derived substance labeled with pigment for fluorescence labeling and reagent containing them. Japan Patent 50401221. 1993 Feb 19.
- Wolf G. Friedrich Miescher, the man who discovered DNA. http://www.bizgraphic.ch/miescheriana/html/the_man_who_discovered_dna.html (Accessed February 2009).
- Altmann R. Ueber nucleinsauren. *Archiv Anat Physiol. Physiologische Abteilung*. 1889:524–536. [German]
- Choudhuri S. Some major landmarks in the path from nuclein to human genome. *Toxicol Mechans Methods* 2006;16:137–59.
- Watson JD, Crick FHC. Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. *Nature (Lond)* 1953;171:737–8.
- Udenfriend S, Zaltzman P. Fluorescence characteristics of purines, pyrimidines, and their derivatives: measurement of guanine in nucleic acid hydrolyzates. *Anal Biochem* 1962;3:49–59.
- Rabinowitz HM. A correlation of fluorescence of human urine with benign and malignant growth. *Cancer Res* 1949;9:672–6.
- Schiller AA. Quantitative measurement of cutaneous fluorescein fluorescence as indicator of the capillary circulation. *Proc Soc Exp Biol Med* 1949;72:594–8.
- Hadding AR. Mineralienanalyse nach röntgenspektroskopischer methode. *Zeitschrift Anorganisch Allgemeine Chemie* 1922;122:195–200. [German]
- Boerstler EW, inventors. Fluorescence detecting apparatus. US Patent 2,139,797. 1938 Dec 13.
- Wheless LL Jr, Patten SF, inventors; Bausch & Lomb, Inc. assignee. Computerized slit-scan cytofluorometer for automated cell recognition. US Patent 3,657,537. 1972 Apr 18.
- Adams LR, Kamensky LA, inventors; Bio/Physics Systems, Inc. assignee. Method for analysis of blood by optical analysis of living cells. US Patent 3,684,377. 1972 Aug 15.
- Hirschfeld T, inventor; Block Engineering, assignee. Method and apparatus for detecting and classifying nucleic acid particles. US Patent 3,887,312. 1975 Jun 3.
- Falkow S, Moseley SL, inventors; Univ. Washington, assignee. Specific DNA probes in diagnostic microbiology. US Patent 4,358,535. 1982 Nov 9.
- Tchen P, Kourilsky P, Leng M, Cami AB, inventors; Institut Pasteur, assignee. Probe containing a modified nucleic acid recognizable by specific antibodies and use of this probe to detect and characterize a homologous DNA sequence. France Patent 2518775. 1983 Jun 24. US Patent 5,098,825. 1992 Mar 24.
- Heller MJ, Morrison LE, Prevatt WD, Akin C, inventors; Std. Oil Co., assignee. Light-emitting polynucleotide hybridization diagnostic method. European Patent 0070687. 1983 Jan 26.
- Ranki TM, Soderlund HE, inventors; Orion Corp. Ltd., assignee. Detection of microbial nucleic acids by a one-step sandwich hybridization test. US Patent 4,563,419. 1986 Jan 7.
- Ward DC, Langer PR, Waldrop A III, inventors; Yale Univ., assignee. Modified nucleotides and methods of preparing and using same. US Patent 4,711,955. 1987 Dec 8.
- Ward DC, Leary JJ, Brigati DJ, inventors; Yale Univ., assignee. Visualization polymers and their application to diagnostic medicine. US Patent 4,687,732. 1987 Aug 18.
- Smith LM, inventor; Cal. Inst. Technology, assignee. Nucleoside phosphoramidites and oligonucleotides produced therefrom. Great Britain Patent 2153356. 1985 Aug 21.
- Englert DF, Wheeler RJ, inventors; Pharmacia, Inc., assignee. Electrophoresis method and apparatus having continuous detection means. US Patent 4,707,235. 1987 Nov 17.
- Middendorf LR, Brumbaugh JA. inventors; Board of Regents of the Univ. Nebraska, assignee. DNA sequencing. US Patent 4,729,947. 1988 Mar 8.
- Middendorf LR, Bruce JC, Bruce RC, Eckles RD, Grone DL, Roemer SC, Sloniker GD, et al. Continuous, on-line DNA sequencing using a versatile infrared laser scanner/electrophoresis apparatus. *Electrophoresis* 1992;13:487–94.
- Heyroth FF, Loofbrow JR. Changes in the ultraviolet absorption spectrum of uracil and related compounds under the influence of radiations. In: *Medicinal chemistry*. Indianapolis: American Chemical Society; 1931. p 3441–553.
- Konev SV. Fluorescence spectra and spectra of action of fluorescence in some proteins. *Dokl Akad Nauk USSR* 1957;116:594–7.
- Konev SV. Fluorescence and phosphorescence of proteins and nucleic acids. New York: Plenum Press; 1967. p 141–6.
- RajBhandary UL, Chang SH, Stuart A, Faulkner RD, Hoskinson RM, Khorana HG. Studies on polynucleotides, LXVIII. The primary structure of yeast phenylalanine transferase RNA. *Proc Natl Acad Sci U S A* 1967;57:751–8.
- Yoshikami D, Keller EB. Chemical modification of the fluorescent base in phenylalanine transfer ribonucleic acid. *Biochemistry* 1971;10:2969–76.
- Yang C, Söll D. Covalent attachment of fluorescent groups to transfer ribonucleic acid: reactions with 4-bromomethyl-7-methoxy-2-oxo-2H-benzopyran. *Biochemistry* 1974;13:3615–21.
- Yang CH, Söll D. Studies of transfer RNA tertiary structure of singlet-singlet energy transfer. *Proc Natl Acad Sci U S A* 1974;71:2838–42.
- Favre A, Yaniv M, Michelson AM. The photochemistry of 4-thiouridine in *Escherichia coli* t-RNA Val1. *Biochem Biophys Res Com* 1969;37:266–71.
- Pochon F, Leng M, Michelson AM. Photochemistry of polynucleotides. III. Study of the fluorescence of polynucleotides at ordinary temperature. *Biochim Biophys Acta* 1968;169:350–62.
- Pochon F, Balny C, Scheit KH, Michelson AM. The photochemistry of polynucleotides. V. Stud-

- ies on 4-thiouridine-containing polymers. *Biochim Biophys Acta* 1971;228:49–56.
54. Ullman EF, Schwarzbarg M, Rubenstein KE. Fluorescent excitation transfer immunoassay: a general method for determination of antigens. *J Biol Chem* 1976;251:4172–8.
 55. Kriek E, Miller JA, Juhl U, Miller EC. 8-(*N*-2-fluorenylacetyl)guanosine, an arylamidation reaction product of guanosine and the carcinogen *N*-acetoxy-*N*-2-fluorenylacetylamine in neutral solution. *Biochemistry* 1967;6:177–82.
 56. Oser A, Valet G. Improved detection by time-resolved fluorometry of specific DNA immobilized in microtiter wells with europium/metal-chelator labeled DNA probes. *Nucleic Acids Res* 1988;16:8178.
 57. Patonay G, Narayanan N, Strekowski L, Midden-dorf LR, Lipowska M, inventors; Licor Inc., assignee. A method for identifying strands of DNA using infrared fluorescence labels. European Patent 0670374. 1995 Sep 12.
 58. Yang Y, Lowry M, Xu X, Escobedo JO, Sibirian-Vazquez M, Wong L, et al. Semianaphthofluorones are a family of water-soluble, low molecular weight, NIR-emitting fluorophores. *Proc Natl Acad Sci U S A* 2008;105:8829–34.
 59. Lacenere CJ, Garg NK, Stoltz BM, Quake SR. Effects of a modified dye-labeled nucleotide spacer arm on incorporation by thermophilic DNA polymerases. *Nucleosides Nucleotides Nucleic Acids* 2006;25:9–15.
 60. Castro SL, Barbera-Guillem E, inventors; Bio-Crystal Ltd., assignee. Functionalized nanocrystals and their use in detection systems. US Patent 6,114,038. 2000 Sep 5.
 61. Barbera-Guillem E, Nelson M, Castro SL, inventors; Bio-Pixels Ltd., assignee. Functionalized nanocrystals and their use in labeling for strand synthesis or sequence determination. US Patent 6,221,602. 2001 Apr 24.
 62. Weiss S, Bruchez M Jr, Alivisatos P, inventors; Regents of the Univ. of California, assignee. Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes. US Patent 5,990,479. 1999 Nov 23.
 63. Li W-LR, Zhou JS, inventors; Monsanto Technology LLC, assignee. Fluorescent oligonucleotides and uses thereof. US Patent 6,838,244. 2005 Jan 4.
 64. Hannah EC, inventor; Intel Corp., assignee. Carbon nanotube molecular labels. US Patent 6,821,730. 2004 Nov 23.
 65. Jeng ES, Moll AE, Roy AC, Gastala JB, Strano MS. Detection of DNA hybridization using the near-infrared band gap fluorescence of single-walled carbon nanotubes. *Nano Lett* 2006;6:371–5.
 66. Zhou X, Zhou J. Improving the signal sensitivity and photostability of DNA hybridizations on microarrays by using dye-doped core-shell silica nanoparticles. *Anal Chem* 2004;76:5302–12.
 67. Li Z-P, Kambara H. Single nucleotide polymorphism analysis based on minisequencing coupled with a fluorescence microsphere technology. *J Nanosci Nanotech* 2005;5:1256–60.
 68. Taylor JR, Fang MM, Nie S. Probing specific sequences on single DNA molecules with bio-conjugated fluorescent nanoparticles. *Anal Chem* 2000;72:1979–86.
 69. Chandler DJ, inventor; Luminex Corp., assignee. Encapsulation of discrete quanta fluorescent particles. US Patent 6,528,165. 2003 Mar 3.
 70. Wieder I, inventor; Analytical Radiation, Inc., assignee. Method and apparatus for improved analytical fluorescent spectroscopy. US Patent 4,058,732. 1977 Nov 15.
 71. Soini E, Hemmila I, inventors; Wallac Oy (Finland), assignee. Fluorescence spectroscopy assay means with fluorescent chelate of a lanthanide. US Patent 4,374,120. 1983 Feb 15.
 72. Hemmila I, Dakubu S, Wallac Oy (Finland), assignee. Method for fluorescence spectroscopic determination of a biologically active substance. US Patent 4,565,790. 1986 Jan 21.
 73. Ekimov AI, Onushchenko AA. Quantum size effect in three-dimensional microscopic semiconductor crystals. *JETP Lett* 1981;34:345–9.
 74. Rossetti R, Nakahara S, Brus LE. Quantum size effects in the redox potentials, resonance Raman spectra, and electronic spectra of CdS crystallites in aqueous solution. *J Chem Phys* 1983;79:1086–8.
 75. Evident Technologies. <http://www.evidenttech.com> (Accessed February 2009).
 76. Bruchez M Jr, Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. *Science (Wash DC)* 1998;1998:281:2013–6.
 77. Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. *Science (Wash DC)* 1998;281:2016–8.
 78. Lawton C, Conroy S, inventors; Univ. of Massachusetts Lowell, assignee. Biomolecular synthesis of quantum dot composites. US Patent 5,985,353. 1999 Nov 16.
 79. Mooradian A. Photoluminescence of metals. *Phys Rev Lett* 1969;22:185–7.
 80. Li C-Z, Male KB, Hrapovic S, Luong JHT. Fluorescence properties of gold nanorods and their application for DNA biosensing. *Chem Comm* 2005;31:3924–6.
 81. Wilcoxon JP, Martin JE, Parsapour F, Wiedeman B, Kelley DF. Photoluminescence from nanosize gold clusters. *J Chem Phys* 1998;108:9137–43.
 82. Wu M, Davidson N. Transmission electron microscopic method for gene mapping on polytene chromosomes by in situ hybridization. *Proc Natl Acad Sci U S A* 1981;78:7059–63.
 83. Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ. A DNA-based method for rationally assembling nanoparticles into macroscopic materials. *Nature (Lond)* 1996;382:607–9.
 84. O'Connell MJ, Bachilo SM, Huffman CB, Moore VC, Strano MS, Haroz EH, Rialon KL, et al. Band gap fluorescence from individual single-walled carbon nanotubes. *Science (Wash DC)* 2002;297:593–6.
 85. Kochetov NK, Shibaev VN, Kost AA. New reaction of adenine and cytosine derivatives potentially useful for nucleic acid modifications. *Tetrahedron Lett* 1971;1933–6.
 86. Bolton PH, Kearns DR. Spectroscopic properties of ethidium monoazide: a fluorescent photo-affinity label for nucleic acids. *Nucleic Acids Res* 1978;5:4891–903.
 87. Tso PO, Lu P. Interaction of nucleic acids, II. Chemical linkage of the carcinogen 3,4-benzpyrene to DNA induced by photoradiation. *Proc Natl Acad Sci U S A* 1964;51:272–80.
 88. Chieco P, Derenzini M. The Feulgen reaction 75 years on. *Histochem Cell Biol* 1999;111:345–58.
 89. Ornstein L, Mautner W, Davis BJ, Tamura R. New horizons in fluorescence microscopy. *J Mt Sinai Hosp N Y* 1957;24:1066–78.
 90. Kasten FH, Burton V, Glover P. Fluorescent Schiff-type reagents for cytochemical detection of polyaldehyde moieties in sections and smears. *Nature (Lond)* 1959;184:1797–8.
 91. Churchich JE. Fluorescence studies on soluble ribonucleic acid labeled with acriflavine. *Biochim Biophys Acta* 1963;75:274–6.
 92. Bienvenüe A, Tournon J. Specific labelling in the 3' and 5' OH position of a nucleoside with a fluorescent dye. *Biochimie* 1973;55:1167–9.
 93. Tournon J. Fluorescence probing of nucleic acids: I. Singly and doubly labeled dithymidine phosphate: fluorescence and energy transfer studies. *Nucleic Acids Res* 1975;2:1261–73.
 94. Menzel HM. On the Phe-tRNA induced binding of fluorescent oligonucleotides to the ribosomal decoding site. *Nucleic Acids Res* 1977;4:2881–92.
 95. Smith LM, Fung S, Hunkapiller MW, Hunkapiller TJ, Hood LE. The synthesis of oligonucleotides containing an aliphatic amino group at the 5' terminus: synthesis of fluorescent DNA primers for use in DNA sequence analysis. *Nucleic Acids Res* 1985;13:2399–412.
 96. Hiratsuka T, Uchida K. Preparation and properties of 2'-(or 3')-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate, an analog of adenosine triphosphate. *Biochim Biophys Acta* 1973;320:635–47.
 97. Yang CH, Söll D. Covalent attachment of fluorescent groups to the 5'-end of transfer RNA. *Arch Biochem Biophys* 1973;155:70–81.
 98. Gohlke JR, Hedaya E, Kang J, Mier JD, inventors; Baker Inst. Corp., assignee. Novel chromogenic and/or fluorogenic substrates for monitoring catalytic or enzymatic activity. US Patent 4,378,458. 1983 Mar 28.
 99. Fidanza JA, McLaughlin LW. Introduction of reporter group at specific sites in DNA containing phosphorothiodate diesters. *J Am Chem Soc* 1989;111:9117–9.
 100. Musajo L, Rodighiero G. A new photo-reaction between some furocoumarins and flavin mononucleotide. *Nature (Lond)* 1961;190:1109–10.
 101. Dall'Acqua F. Studies on the photoreaction (365 nm) between psoralen and thymine. *Scienze Chimiche* 1968;38:1094–9.
 102. Musajo L, Rodighiero G. The skin-photosensitizing furocoumarins. *Experientia* 1962;18:153–61.
 103. Musajo L, Rodighiero G, Colombo G, Torlone V, Dall'Acqua F. Photosensitizing furocoumarins: interaction with DNA and photo-inactivation of DNA containing viruses. *Experientia* 1965;21:22–4.
 104. Musajo L, Rodighiero G, Dall'Acqua F. Evidences of a photoreaction of the photosensitizing furocoumarins with DNA and with pyrimidine nucleosides and nucleotides. *Experientia* 1965;21:24–6.
 105. Musajo L, Rodighiero G. The mechanism of action of the skin photosensitizing furocoumarins. *Acta Derm Venereol* 1967;47:298–303.
 106. Musajo L, Visentini P, Bacchinetti F, Razzi MA. Photoinactivation of Ehrlich ascites tumor

- cells in vitro obtained with skin-photosensitizing furocoumarins. *Experientia* 1967;23:335–6.
107. Lee YJ, Summers WA, Burr JG. Fluorescent and phosphorescent pyrimidine labels: α -diketone derivative of uracil and thymine. *Tetrahedron* 1978;34:2861–8.
 108. Sato T, Okahata Y, inventors; Tokyo Institute of Technology (Japan), assignee. Fluorescence-labeled probe for DNA and a fluorescence-labeled plasmid. US Patent 6,608,213. 2003 Aug 19.
 109. Pochon F, Perrin M. Fluorescent labelling of polynucleotides by 9-bromomethylanthracene. *Eur J Biochem* 1974;43:107–13.
 110. Barrio JR, Secrist JA 3rd, Leonard NJ. A fluorescent analog of nicotinamide adenine dinucleotide. *Proc Natl Acad Sci U S A* 1972;69:2039–42.
 111. Secrist JA 3rd, Barrio JR, Leonard NJ. A fluorescent modification of adenosine triphosphate with activity in enzyme systems: 1,N 6-ethenoadenosine triphosphate. *Science (Wash DC)* 1972;175:646–7.
 112. Saito I, Ito S, Shinmura T, Metsuura T. A simple synthesis of fluorescent uridines by photochemical method. *Tetrahedron Lett* 1980;21:2813–6.
 113. Gillam I, Blew D, Warrington RC, von Tigerstrom M, Tener GM. A general procedure for the isolation of specific transfer ribonucleic acids. *Biochemistry* 1968;7:3459–68.
 114. Lynch DC, Schimmel PR. Cooperative binding of magnesium to transfer ribonucleic acid studied by a fluorescent probe. *Biochemistry* 1974;13:1841–52.
 115. Limbach PA, Crain PF, McCloskey JA. Summary: the modified nucleosides of RNA. *Nucleic Acid Res* 1994;22:2183–96.
 116. Secrist JA 3rd, Barrio JR, Leonard NJ. Attachment of a fluorescent label to 4-thiouracil and 4-thiouridine. *Biochem Biophys Res Commun* 1971;45:1262–70.
 117. Favre A, Yaniv M. Introduction of an intramolecular fluorescent probe in *E. coli* tRNA(Val)(1). *FEBS Lett* 1971;17:236–40.
 118. Favre A, Thomas G. Transfer RNA: from photophysics to photobiology. *Annu Rev Biophys Bioeng* 1981;10:175–95.
 119. Rozovskaia TA, Bibilashvili PSh, Tarusova NB, Gurskii GV, Strel'tsov SA. Addition of the fluorescent label to the 3'-OH end of DNA and the 3'-OH end of nascent RNA. *Mol Biol (Mosk)* 1977;11:598–610. [Russian]
 120. Eshaghpour H, Söll D, Crothers DM. Specific chemical labeling of DNA fragments. *Nucleic Acids Res* 1979;7:1485–95.
 121. Richardson RW, Gumpert RI. Biotin and fluorescent labeling of RNA using T4 RNA ligase. *Nucleic Acids Res* 1983;11:6167–84.
 122. Dunn DA, Lin VH, Kochevar IE. The role of ground state complexation in the electron transfer quenching of methylene blue fluorescence by purine nucleotides. *Photochem Photobiol* 1991;51:47–56.
 123. Armstrong JA, Niven JS. Fluorescence microscopy in the study of nucleic acids: histochemical observations on cellular and virus nucleic acids. *Nature (Lond)* 1957;180:1335–6.
 124. Mikhailov MV, Zasedatelev AS, Krylov AS, Gurskii GV. Mechanism of AT base pairs recognition by molecules of dye "Hoechst 33258." *Mol Biol (Mosk)* 1981;15:690–705.
 125. Nordén B, Tjernelid F, Palm E. Linear dichroism studies of binding site structures in solution: complexes between DNA and basic arylmethane dyes. *Biophys Chem* 1978;8:1–15.
 126. von Provazek S. Über fluoreszenz der zellen. *Kleinwelt* 1914;6:30. [German]
 127. Clark G, Kasten FH. History of staining, 3rd ed. Baltimore: Williams and Wilkins; 1983. 304 p.
 128. Seaman A, Woodbine M. The antibacterial activity of phenanthridine compounds. *Br J Pharmacol Chemother* 1954;9:265–70.
 129. Lerman LS. Structural considerations in the interaction of DNA and acridines. *J Mol Biol* 1961;3:18–30.
 130. Elliott WH. The effects of antimicrobial agents on deoxyribonucleic acid polymerase. *Biochem J* 1963;86:562–7.
 131. Le Pecq JB, Yot P, Paoletti C. Interaction du bromohydrate d'ethidium (BET) avec les acides nucléiques. Etude spectrofluorométrique. *CR Acad So Paris* 1964;259:1786–9. [French]
 132. Waring MJ. Complex formation between ethidium bromide and nucleic acids. *J Mol Biol* 1965;13:269–82.
 133. Gaugain B, Barbet J, Oberlin R, Roques BP, Le Pecq JB. DNA bifunctional intercalators. I. Synthesis and conformational properties of an ethidium homodimer and of an acridine ethidium heterodimer. *Biochemistry* 1978;17:5071–8.
 134. Lee LG, Chen CH, Chiu LA. Thiazole orange: a new dye for reticulocyte analysis. *Cytometry* 1986;7:508–17.
 135. Glazer AN, Rye HS. Stable dye-DNA intercalation complexes as reagents for high-sensitivity fluorescence detection. *Nature (Lond)* 1992;359:859–61.
 136. Singer VL, Jones LJ, Yue ST, Haugland RP. Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation. *Anal Biochem* 1997;249:228–38.
 137. Le Pecq JB, Paoletti C. Interaction of ethidium hydrobromate (EH) with polyribonucleotides. Applications to the study of hybridization reactions. *Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences-D: Sciences Naturelles* 1965;260:7033–6.
 138. Le Pecq JB, Paoletti C. Study of displacement reactions between polyribonucleotides by use of ethidium hydrobromate (ETB): demonstration of displacement of the poly (A-2 I) by poly U. *Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences-D: Sciences Naturelles* 1965;261:838–41.
 139. Borst P. Ethidium bromide agarose gel electrophoresis: how it started. *IUBMB Life* 1005;57:745–7.
 140. Aaij C, Borst P. The gel electrophoresis of DNA. *Biochim Biophys Acta* 1972;269:192–200.
 141. Sharp PA, Sugden B, Sambrook J. Detection of two restriction endonuclease activities in *Haemophilus parainfluenzae* using analytical agarose-ethidium bromide electrophoresis. *Biochemistry* 1973;12:3055–63.
 142. Mayor HD, Diwan AR. Studies on the acridine orange staining of two purified RNA viruses: poliovirus and tobacco mosaic virus. *Virology* 1961;14:74–82.
 143. Tas J, Mendelson D, Noorden CJ. Cuproline blue: a specific dye for single-stranded RNA in the presence of magnesium chloride. I. Fundamental aspects. *Histochem J* 1983;15:801–14.
 144. Rye HS, Dabora JM, Quesada MA, Mathies RA. Fluorometric assay using dimeric dyes for double- and single-stranded DNA and RNA with pictogram sensitivity. *Anal Biochem* 1993;208:144–50.
 145. Labarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. *Anal Biochem* 1980;102:344–52.
 146. Mergny J-L, Collier D, Rougee M, Montenat-Garestier T, Helene C. Intercalation of ethidium bromide into triple-stranded oligonucleotide. *Nucleic Acids Res* 1991;19:1521–6.
 147. Latt SA, Wohlleb JC. Optical studies of the interaction of 33258 Hoechst with DNA, chromatin, and metaphase chromosomes. *Chromosoma* 1975;52:297–316.
 148. Bunkenborg J, Stidsen MM, Jacobsen JP. On the sequence selective bis-intercalation of a homodimeric thiazole orange dye in DNA. *Bioconjugate Chem* 1999;10:824–31.
 149. Vener TI, Turchinsky MF, Knorre VD, Lukin YV, Shcherbo SN, Zubov VP, Sverdlov ED. A novel approach to non-radioactive hybridization assay of nucleic acids using stained latex particles. *Anal Biochem* 1991;198:308–11.
 150. Langer-Safer PR, Levine M, Ward DC. Immunological method for mapping genes on *Drosophila* polytene chromosomes. *Proc Natl Acad Sci U S A* 1982;79:4381–5.
 151. Bauman JG, Wiegant J, van Duijn P. Cytochemical hybridisation with fluorochrome-labelled RNA. III. Increased sensitivity by the use of anti-fluorescein antibodies. *Histochemistry* 1981;73:181–93.
 152. Rule GS, Montagna RA, Durst RA. Rapid method for visual identification of specific DNA sequences based on DNA-tagged liposomes. *Clin Chem* 1996;42:1206–9.
 153. Crisman HA, Stevenson AP, Orlicky DJ, Kissane RJ. Detailed studies on the application of three fluorescent antibiotics for DNA staining in flow cytometry. *Stain Technol* 1978;53:321–30.
 154. Lewis PN. Fluorescently labelled histones as probes of nucleosome structure: preparation and general properties of methionine-labelled histone H4. *Eur J Biochem* 1979;99:315–22.
 155. Beiser SM, Andres GA, Christian CL, Hsu KC, Seegal BC. Immunological studies of lupus-like nephritis in NZB/NZW F1 mice [Abstract]. *Federation Proc* 1968;27:621, A2282.
 156. Benjaminson MA, Hunter DB, Katz JJ. Fluorochrome-labelled deoxyribonuclease: specific stain for cell nuclei. *Science (New York, NY)* 1968;160:1359–60.
 157. Cheung SW, Tishler PV, Atkins L, Sengupta SK, Modest EJ, Forget BC. Gene mapping by fluorescent in situ hybridization [Abstract]. *J Cell Biol* 1976;70:221A.
 158. Cheung SW, Tishler PV, Atkins L, Sengupta SK, Modest EJ, Forget BG. Gene mapping by fluorescent in situ hybridization. *Cell Biol Int Rep* 1977;1:255–62.
 159. Stollar BD. Double-helical polynucleotides: immunochemical recognition of differing conformations. *Science (Wash DC)* 1970;169:609–11.

160. Rudkin GT, Stollar BD. High resolution detection of DNA-RNA hybrids in situ by indirect immunofluorescence. *Nature (Lond)* 1977;265:472-3.
161. Stuart WD, Frank MB, inventors; Univ. of Hawaii, assignee. Monoclonal antibodies for DNA-RNA hybrid complexes and their uses. US Patent 4,732,847. 1988 Mar 22.
162. Beardsley K, Cantor CR. Studies of transfer RNA tertiary structure by singlet-singlet energy transfer. *Proc Natl Acad Sci U S A* 1970; 65:39-46.
163. Gelfand D, Holland P, Saiki R, Watson R. inventors; Hoffman-La Roche Inc., assignee. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase. US Patent 5,210,015. 1990 Aug 6.
164. Ju J, inventor; Incyte Pharmaceuticals, Inc., assignee. Sets of labeled energy transfer fluorescent primers and their use in multi component analysis. US Patent 5,804,386. 1998 Sep 8.
165. Soderlund HE, Weckman AM, inventors; Orion-Yahtyma Oy, assignee. Method for assays of nucleic acid: a reagent combination and kit therefor. US Patent 5,476,769. 1995 Dec 19.
166. Tyagi S, Kramer FR, Lizardi PM, inventors; Public Health Research Institute of the City of New York, Inc., assignee. Detectably labeled dual conformation oligonucleotide probes, assays and kits. US Patent 5,925,517. 1999 Jul 20.
167. Tyagi S, Kramer FR. Molecular beacons: probes that fluoresce upon hybridization. *Nat Biotechnol* 1996;14:303-8.
168. Eisinger J, Gueron M, Shulman RG, Yamane T. Excimer fluorescence of dinucleotides, polynucleotides, and DNA. *Proc Natl Acad Sci U S A* 1966;55:1015-20.
169. Gueron M, Shulman RG, Eisinger J. Energy transfer in dinucleotides. *Proc Natl Acad Sci U S A* 1966;55:814-8.
170. Lipsett MN. The behavior of 4-thiouridine in the *E. coli* s-RNA molecule. *Biochem Biophys Res Comm* 1965;20:244-9.
171. Jeffrey AM, Jennette KW, Blobstein SH, Weinstein IB, Beland FA, Harvey RG, et al. Benzo[a]pyrene-nucleic acid derivative found in vivo: structure of a benzo[a]pyrenetetrahydrodiol epoxide-guanosine adduct. *J Am Chem Soc* 1976;98:5714-5.
172. Koreeda M, Moore PD, Yagi H, Yeh HJ, Jerina DM. Alkylation of polyguanylic acid at the 2-amino group and phosphate by the potent mutagen (+/-)-7beta, 8alpha-dihydroxy-9beta, 10beta-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. *J Am Chem Soc* 1976;98:6720-2.
173. Casperson T, Farber S, Foley GE, Kudynowski J, Modest EJ, Simonsson E, et al. Chem differentiation along metaphase chromosomes. *Exp Cell Res* 1968;49:219-22.
174. Draper DE, Gold L. A method for linking fluorescent labels to polynucleotides: application to studies of ribosome-ribonucleic acid interactions. *Biochemistry* 1980;19:1774-81.
175. Leng M, Pochon F, Michelson AM. [Photochimie des polynucleotides, II Etude de la luminescence a temperature ordinaire de mononucleotides et dinucleotides]. *Biochem Biophys Acta* 1968;169: 338-49.
176. Yoshida S, Hirose S, Iwamoto M. Use of 4-bromomethyl-7-methoxycoumarin for derivatization of pyrimidine compounds in serum analysed by high-performance liquid chromatography with fluorometric detection. *J Chromatogr* 1986;383:61-8.
177. Pingoud A, Boehme D, Riesner D, Kownatzki R, Maass G. Anti-cooperative binding of two tRNATyr molecules to tyrosyl-tRNA synthetase from *Escherichia coli*. *Eur J Biochem* 1975;56: 617-22.
178. Schiller PW, Schechter AN. Covalent attachment of fluorescent probes to the X-base of *Escherichia coli* phenylalanine transfer ribonucleic acid. *Nucleic Acids Res* 1977;4:2161-7.
179. Faulhammer HG, Sprinzl M, Cramer F. Fluorescamine modification of *E. coli* and yeast transfer RNAs and their use in the study of protein biosynthesis [Abstract]. In: Miriam Balaban, ed. Molecular mechanisms of biological recognition: proceedings of the sixth Aharon Katzir-Katchalsky Conference, in conjunction with the Minerva Symposium in Biology, Göttingen and Braunlage/Harz, September 24-30, 1978. Amsterdam; New York: Elsevier/North-Holland Biomedical Press; 1979. Eigen M and Cramer F, organizers.
180. Kasai H, Shindo-Okada N, Noguchi S, Nishimura S. Specific fluorescent labeling of 7-(aminomethyl)-7-deazaguanosine located in the anticodon of tRNA-Tyr isolated from *E. coli* mutant. *Nucleic Acids Res* 1979;7:231-8.
181. Kuchino Y, Kasai H, Yamaizumi Z, Nishimura S, Borek E. Under-modified Y base in a tRHAPhe isoacceptor observed in tumor cells. *Biochim Biophys Acta* 1979;565:215-8.
182. Macklin JJ, Trautman JK, Harris TD, inventors; Seq Ltd., assignee. Method to make fluorescent nucleotide photoproducts for DNA sequencing and analysis. World Intellectual Property Organization (WO) Patent 013110. 1999 Mar 18.
183. Ward DC, Cerami A, Reich E, Acs G, Altwerger L. Biochemical studies of the nucleoside analogue, formycin. *J Biol Chem* 1969;244:3243-50.
184. Ward DC, Reich E, Stryer L. Fluorescence studies of nucleotides and polynucleotides. I. Formycin, 2-aminopurine riboside, 2,6-diaminopurine riboside, and their derivatives. *J Biol Chem* 1969; 244:1228-37.
185. Zhenodarova SM, Klyagina VP. Step-wise oligonucleotide synthesis. XXV. Synthesis of trinucleoside diphosphates containing a fluorescent label. *Bioorg Khim* 1977;3:1623-5.
186. Ried T, Baldini A, Rand TC, Ward DC. Simultaneous visualization of seven different DNA probes by in situ hybridization using combinatorial fluorescence and digital imaging microscopy. *Proc Natl Acad Sci U S A* 1992;89: 1388-92.
187. Prober JM, Trainor GL, Dam RJ, Hobbs FW, Robertson CW, Zagursky RJ, et al. A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. *Science (Wash DC)* 1987;238:336-41.